Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetic associations with long-term response to anti-vascular endothelial growth factor treatment in neovascular AMD patients.

Molecular vision - 1 Jan 2014

Park Un Chul, Shin Joo Young, McCarthy Linda C, Kim Sang Jin, Park Jung Hyun, Chung Hum, Yu Hyeong Gon

Abstract excerpt

PURPOSE: To investigate the pharmacogenetic associations between the genetic risk variants of age-related macular degeneration (AMD) and long-term outcome after intravitreal anti-vascular endothelial growth factor (VEGF) treatment in Korean neovascular AMD patients. METHODS: This prospective study included 394 treatment-naïve patients (394 eyes) that underwent intravitreal anti-VEGF treatment for neovascular AMD...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiogenesis Inhibitors
Share to Bevacizumab

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to High-Temperature Requirement A Serine Peptidase 1

Share to Macular Degeneration

Share to Republic of Korea

Share to Serine Endopeptidases

Share to Vascular Endothelial Growth Factor A

Share to Visual Acuity

Source

Open in PubMed Open full text

Identifiers

PMID: 25558172
PMCID: PMC4278401

Genes

ARMS2
HTRA1
VEGFA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetic associations with long-term response to anti-vascular endothelial growth factor treatment in neovascular AMD patients.PMID 25558172Read ↗

Genetic factors associated with response to intravitreal ranibizumab in Korean patients with neovascular age-related macular degeneration.Semantic proximity Read ↗

Genetic influences on the outcome of anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration.Semantic proximity Read ↗

Pharmacogenetic association with early response to intravitreal ranibizumab for age-related macular degeneration in a Korean population.Semantic proximity Read ↗

Long-term outcome of neovascular age-related macular degeneration: association between treatment outcome and major risk alleles.Semantic proximity Read ↗

Genetic biomarkers in the VEGF pathway predicting response to anti-VEGF therapy in age-related macular degenerationSemantic proximity Read ↗

Association of Genetic Variants With Response to Anti-Vascular Endothelial Growth Factor Therapy in Age-Related Macular Degeneration.Semantic proximity Read ↗

VEGF gene polymorphism and response to intravitreal ranibizumab in neovascular age-related macular degeneration.Semantic proximity Read ↗

Influence of Genetic Polymorphisms on the Short-Term Response to Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration.Semantic proximity Read ↗

Common variant in VEGFA and response to anti-VEGF therapy for neovascular age-related macular degeneration.Semantic proximity Read ↗

Association between VEGF-A and VEGFR-2 polymorphisms and response to treatment of neovascular AMD with anti-VEGF agents: a meta-analysis.Semantic proximity Read ↗

Predictive value of VEGF A and VEGFR2 polymorphisms in the response to intravitreal ranibizumab treatment for wet AMD.Semantic proximity Read ↗

A prospective multicenter study on genome wide associations to ranibizumab treatment outcome for age-related macular degeneration.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.